---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Prevalence"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Prevalence. Topics: US adults with NASH and non-cirrhotic F2 to F3 fibrosis: prevalence inputs of an eligible-population model; US adults with NASH and moderate to severe fibrosis: ICER budget impact population, 2023 to 2027; US adults meeting liberal and restrictive resmetirom eligibility criteria, NHANES 2017 to March 2020; US adults with NAFLD: at-risk NASH by FAST score (proxy for NAS of 4 or more and F2 or higher), NHANES 2017 to 2018; 14 further topics. 18 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/prevalence"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="topic-2.2.1.2.2-1"></a>

### US adults with NASH and non-cirrhotic F2 to F3 fibrosis: prevalence inputs of an eligible-population model

> “In the base case, a NASH prevalence of 4.6% was modeled (range 1.3–14.2%). This value was multiplied by the proportion estimated to have non-cirrhotic MALF (i.e., 35%).”
> “Therefore, taking patient counts estimates using FIB-4 for F2 and F3 over the total subgroup patient count, we get (3735 + 2725)/18,612 ≈ 35% of the patients were diagnosed with F2/F3 NASH (Table 1)”
> “Assuming a 1-million commercial-member population, the resmetirom treatment-eligible population was estimated as 1255–1699 in Years 1–3 following approval.”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.1.2.2-2"></a>

### US adults with NASH and moderate to severe fibrosis: ICER budget impact population, 2023 to 2027

> “we applied a prevalence estimate of 1.4% to the 2023-2027 projected US population aged 18 years of age and older.”
> “Our estimate was based on a 4% prevalence of NASH in the overall US population [based on a reported average of 1.5% to 6.5%]”
> “the proportion of patients with NASH who have moderate to severe fibrosis which was reported to be 35%.”
> “Applying these sources resulted in an average estimated prevalence of 3.81 million eligible patients in the US.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-2.2.1.2.2-3"></a>

### US adults meeting liberal and restrictive resmetirom eligibility criteria, NHANES 2017 to March 2020

> “Two eligibility scenarios were examined: a liberal scenario requiring ALT >17 U/L for women or >20 U/L for men, controlled attenuation parameter (CAP) >280 dB/m, and liver stiffness measurement (LSM) >8 kPa; and a restrictive scenario requiring ALT >30 U/L for both sexes, CAP >280 dB/m, and LSM >10 kPa.”
> “An estimated 8.3 million (95% CI: 6.6–9.9 million) adults met the liberal eligibility criteria, while 2.3 million (95% CI: 1.4–3.2 million) met the restrictive criteria.”
> “Among adults with T2DM, 3.5 million (95% CI: 2.4–4.5 million; 12.2%) met liberal, whereas 0.85 million (95% CI: 0.5–1.2 million; 3.0%) restrictive criteria.”

Source: [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/)

<a id="topic-2.2.1.2.2-4"></a>

### US adults with NAFLD: at-risk NASH by FAST score (proxy for NAS of 4 or more and F2 or higher), NHANES 2017 to 2018

> “Patients with a FAST score >0.35 were considered to have at-risk NASH, defined as NASH with NAFLD activity score ≥4 and fibrosis stage ≥2 on liver biopsy.”
> “The overall prevalence of at-risk NASH was 11.6% (95% CI: 8.8–15.1) and was higher in males than females (15.8% vs. 6.5%; p < 0.001).”
> “We estimated ~9 million people in the US have at-risk NASH and may benefit from active surveillance and therapy.”

Source: [Payne et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9833447/)

<a id="topic-2.2.1.2.2-5"></a>

### US adults with MASLD by liver stiffness: 8 to 12 kPa and 12 kPa or higher, NHANES 2017 to 2020

> “In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8–12 kPa and 6% LSM ≥12 kPa.”

Source: [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/)

<a id="topic-2.2.1.2.2-6"></a>

### US adults aged 50 years or older with type 2 diabetes: MASLD, at-risk MASH, and cirrhosis, prospective cohort 2016 to 2023

> “This prospective study enrolled adults age ≥ 50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023.”
> “Among patients with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis was 69.6%, 13.6%, and 6.8%, respectively.”
> “At-risk MASH was defined by an either positive MEFIB score (MRE > 3.3 kPa + Fib4 > 1.6), FAST score ≥ 0.67, or MAST score ≥ 0.242”

Source: [Mittal et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12425555/)

<a id="topic-2.2.1.2.2-7"></a>

### US adults with SLD, MASLD, and MetALD, NHANES January 2017 to March 2020

> “Among 7367 participants, 2549 met the new definition for SLD (mean age 51 years, 57.7% male, 63.2% non-Hispanic White; Table 1).”
> “The estimated prevalence of SLD was 34.2% (95% CI 31.9%–36.5%): MASLD 31.3% (95% CI 29.2%–33.4%), MetALD 2.2% (95%CI 1.6–2.9%), ALD 0.7% (95%CI 0.5–0.9%) and etiology-specific or cryptogenic SLD 0.03% (95% CI 0.01%–0.08%)”
> “In this national study, we estimate the prevalence of SLD to be 34.2% (ie, > 90 million US adults), with MASLD accounting for the majority (31.3%)”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/)

<a id="topic-2.2.1.2.2-8"></a>

### US adults with SLD and MASLD, age-adjusted, and advanced fibrosis in SLD, NHANES 2017 to 2023

> “Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography.”
> “The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1).”
> “In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era.”

Source: [Kim et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12016658/)

<a id="topic-2.2.1.2.2-9"></a>

### US general population with MASLD and MASLD-related cirrhosis, NHANES 2017 to 2020

> “The prevalence of chronic liver disease etiologies was ALD 0.85%, MetALD 3.38%, CHB 0.23%, CHC 0.73%, ALD + viral hepatitis 0.16%, and MASLD 33.05%.”
> “In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.”
> “Individuals with MASLD comprise the majority of US residents with cirrhosis.”

Source: [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/)

<a id="topic-2.2.1.2.2-10"></a>

### US adults with NAFLD and NASH: prevalence and clinically significant fibrosis in AASLD 2023 guidance

> “The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population”
> “The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.”
> “This study also highlights that since the publication of a prior prospective prevalence study,”
> “the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased > 2-fold.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.2.2-11"></a>

### US NAFLD and NASH cases with F3 to F4 fibrosis, 2015 and projected to 2030, Markov model

> “The total NAFLD population in 2015 was estimated at 83.1 million cases (Fig. 3A), with a prevalence rate of 30.0% among the population aged ≥15 years and 25.8% among all ages. By 2030, the NAFLD population was projected to increase 21% to 100.9 million cases.”
> “The number of NASH cases is projected to increase 63% from 16.52 million cases in 2015 to 27.00 million in 2030 (Fig. 3B).”
> “Among NASH cases in 2015, an estimated 20% have F3/F4 fibrosis or advanced liver disease, encompassing approximately 3.31 million cases (Fig. 4). By 2030, this number is expected to increase over 160% to 7.94 million cases and will account for 29% of NASH cases.”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.2.2-12"></a>

### US adults with MASLD, MASH, and MASH with F2 or higher fibrosis, projected 2020 to 2050, microsimulation model

> “The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050. Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F≥F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million.”

Source: [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/)

<a id="topic-2.2.1.2.2-13"></a>

### Global and North American NAFLD prevalence: meta-analysis of studies from 1990 to 2019

> “Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively.”
> “Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001)”
> “Across the entire study period (1990–2019), analysis of the regional prevalence rates showed a prevalence of 31.20% in North America and Australia (95% CI: 25.86%–37.08%)”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="topic-2.2.1.2.2-14"></a>

### Global and North American NASH prevalence: estimate from voluntarily biopsied NAFLD cohorts

> “Subsequently, the NASH prevalence in the general population was estimated by multiplying the prevalence of NASH in the “voluntary biopsied NAFLD” group with the prevalence of NAFLD in the general population.”
> “Our estimates suggest that the global NASH prevalence is 5.27% (SE: 2.63).”
> “North America [5.00% (2.50)]”
> “The prevalence of NASH among NAFLD patients is 16.02% (95% CI: 3.24%–52.08%).”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="topic-2.2.1.2.2-15"></a>

### Global NAFLD prevalence in adults diagnosed by imaging: meta-analysis

> “The overall prevalence of NAFLD worldwide was estimated to be 32·4% (95% CI 29·9-34·9). Prevalence increased significantly over time, from 25·5% (20·1-31·0) in or before 2005 to 37·8% (32·4-43·3) in 2016 or later (p=0·013). Overall prevalence of NAFLD was significantly higher in men than in women (39·7% [36·6-42·8] vs 25·6% [22·3-28·8]; p<0·0001).”

Source: [Riazi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35798021/)

<a id="topic-2.2.1.2.2-16"></a>

### Global NAFLD prevalence and metabolic comorbidities: meta-analysis of studies from 1989 to 2015

> “Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa.”
> “Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05).”

Source: [Younossi et al. (2016a)](https://pubmed.ncbi.nlm.nih.gov/26707365/)

<a id="topic-2.2.1.2.2-17"></a>

### Global NAFLD prevalence forecast to 2040, hierarchical Bayesian model

> “The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%.”

Source: [Le et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9597215/)

<a id="topic-2.2.1.2.2-18"></a>

### UK Biobank participants with liver MRI: SLD, MASLD, and at-risk MASH

> “At-risk MASH was defined as PDFF≥5% and cT1 ≥875 ms”
> “Among 40,189 patients, 10,886 (27.0%) had a PDFF ≥5%, indicating SLD. Among patients with SLD, 1% had ALD, 89.0% had MASLD, 7.9% had MetALD and 2.2% had at-risk MASH. The at-risk MASH group, which included 0.6% of the general population, had the highest mean liver fat on MRI and the highest BMI.”

Source: [Schneider et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12285740/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
